Erivedge FDA Approval History

FDA Approved: Yes (First approved January 30, 2012)
Brand name: Erivedge
Generic name: vismodegib
Dosage form: Capsules
Company: Genentech
Treatment for: Basal Cell Carcinoma

Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell carcinoma (BCC).

Development Timeline for Erivedge

Date	Article
Jan 30, 2012	FDA Approves Erivedge for Basal Cell Carcinoma
Nov  9, 2011	FDA Accepts Genentech's New Drug Application For Vismodegib in Advanced Form of Skin Cancer
Sep 12, 2011	Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer